Product Images Lamivudine
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 3 images provide visual information about the product associated with Lamivudine NDC 65862-055 by Aurobindo Pharma Limited, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1. Virologic Response through Week 48, EPV20001a,b (Intent-to-Treat) - lamivudine figure1
The text describes a figure showing the virologic response through week 48 for EPV200012. It presents the proportions of subjects with HIV-1 RNA less than 400 copies/mL for two treatments: Lamivudine 150 mg twice daily and Lamivudine 300 mg once daily. The figure is plotted over time, showing the treatment time in weeks on the X-axis and the proportion of subjects on the Y-axis. The figure has T and 0 symbols along the X-axis, indicating the time of assessment.*
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL -10 mg/mL (240 mL Bottle Label) - lamivudine figure2
Each milliliter of the oral solution of Lamivudine USP manufactured by Aurobindo Pharma USA, Inc. contains 10 milligrams of Lamivudine USP. The usual dosage should be obtained from the package insert. This drug should be kept out of reach of children and stored at room temperature between 20-25°C (68° to 77°F) with allowed excursions to 15° to 30° (59° to 86°F). The code is TS/DRUGS/10/1993. The warning advises users to replace the cap securely after each 10 mg/mL opening. However, some text is not available.*
Chemical Structure - lamivudine structure
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.